The Global Autoinjectors Market is Estimated to be Valued at USD 79,741 Million by 2024 and is Expected to Register a CAGR of 17.42% During the Forecast Period.
The disposable autoinjectors segment is expected to lead the market and register a substantial CAGR to reach USD 53,696.20 Million by the end of 2024. The increasing demand for testing new drugs and chemicals and vigorous growth in the pharmaceutical and biopharmaceutical sectors are expected to drive the market growth. Additionally, the disposable autoinjectors segment is also projected to exhibit the highest CAGR of 17.90% from 2019 to 2024.
Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6311
Americas accounted for the largest market share of 40.6% in 2018, and the regional market is projected to register a CAGR of 16.60% during the forecast period. Asia-Pacific is expected to register the fastest CAGR. The Indian market is projected to exhibit the highest growth rate of 18.95% during the forecast period of 2019 to 2024.
The Global Autoinjectors Market has been segmented on the basis of product type, design therapeutic application, distribution channel, and region. On the basis of product type, the market has been divided into the disposable autoinjectors and reusable autoinjectors. The disposable autoinjectors segment held the majority market share in 2018. It also was the fastest-growing owing to the increasing demand for testing new drugs and chemicals and vigorous growth in the pharmaceutical and biopharmaceutical sectors.
Market Research Future (MRFR) recognizes Amgen Inc. (US), Becton, Dickinson and Company (US), AbbVie Inc. (US), Mylan N.V. (US), Eli Lilly and Company (US), Ypsomed (Switzerland), Owen Mumford Ltd (UK), Consort Medical (UK), SHL Group (Taiwan), Johnson & Johnson Services Inc. (US), Teva Pharmaceutical Industries Ltd (Israel), Antares Pharma (US) as the key players in the Global Autoinjectors Market.
Geographically, the global autoinjectors market has been segmented into North America, Europe, Asia-Pacific, and the Middle East & Africa. As per MRFR analysis, the Americas was the largest market for the autoinjectors in 2018 and is expected to remain dominant during the review period. Europe accounted for a significant market share and is projected to be the second-largest market during the forecast period. The well-established healthcare infrastructure, technology advancement, and innovation in drug delivery systems, and rising prevalence of anaphylaxis incidences, diabetes, and cancer are driving the growth of the autoinjectors market in the region. Germany accounted for the largest market share of 24.7% in 2018, and the country-level market is projected to register a CAGR of 15.84% during the forecast period.
FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/autoinjectors-market-6311